Stock Market Reviews

Read and share opinions on ABBV (AbbVie Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• BofA Cuts AbbVie (ABBV) Target While Maintaining Neutral View
  Dec 30, 2025
• Top Stock Reports for AbbVie, Coca-Cola & Chevron
  Dec 24, 2025
• ABBV vs. AZN: Which Pharma Stock is the Better Investment Now?
  Dec 23, 2025
• What AbbVie (ABBV)'s Restructured OSE Immunology Partnership Means For Shareholders
  Dec 22, 2025
• 3 Dividend Growth Stocks Analysts Are Upgrading for 2026
  Dec 21, 2025

ABBV News

• Is AbbVie a Buy, Sell, or Hold in 2026?
  It is wrapping up another great year, and there is no sign of a slowdown.
  Dec 27, 2025
• 2 Dividend Stocks to Double Up On Right Now
  If you're hunting for dividend stocks, don't overlook these businesses.
  Dec 27, 2025
• The Best Stocks to Invest $50,000 in Right Now
  If you're investing for the long run, there are a myriad of companies begging to be bought.
  Dec 27, 2025
• This Cancer-Fighting Biotech Surges Into Buy Zone As Earnings Soar 131%
  Investors gave been rotating away from technology. This biotech stock has rallied into a buy zone amid sharp earnings growth.
  Dec 26, 2025
• Top Stock Reports for AbbVie, Coca-Cola & Chevron
  ABBV, KO and CVX headline Zacks' top stock reports as analysts flag growth drivers, strategic moves and key headwinds shaping 2025 outlooks.
  Dec 24, 2025
• 2 Dividend Kings Quietly Beating the Market This Year
  These two are the calm outperformers that might have been overlooked.
  Dec 24, 2025
• 5 Big Drug Stocks That May Continue to Outperform in 2026
  Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026.
  Dec 23, 2025
• ABBV vs. AZN: Which Pharma Stock is the Better Investment Now?
  AbbVie and AstraZeneca both bring blockbuster drugs, deep pipelines and risks, but their growth paths, pressures and priorities now sharply diverge.
  Dec 23, 2025
• 3 Stocks Estimated To Be Trading Below Fair Value By Up To 46%
  As the U.S. stock market continues its upward trajectory, with major indices like the S&P 500 and Dow Jones Industrial Average nearing record highs, investors are increasingly on the lookout for opportunities that may be flying under the radar. In such a climate, identifying stocks that are estimated to be trading below their fair value can offer potential pathways to capitalize on market movements, especially when tech shares lead the charge and precious metals hit fresh records.
  Dec 23, 2025
• Strategists are bullish on healthcare in 2026: 3 top stock picks
  Catalyst Funds chief investment officer and senior portfolio manager David Miller and Marketgauge.com chief strategist Michele Schneider join Morning Brief host Julie Hyman to share some of their top stock picks in the healthcare (XLV) sector. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.
  Dec 23, 2025
• Beyond Botox: AbbVie’s push for broader gains in neurotoxin R&D
  The large pharma is advancing two next-generation neurotoxins in both the therapeutic and aesthetic spaces.
  Dec 23, 2025
• 2026 Rate Cuts Coming as Inflation Drops: 5 Quality Dividend Stocks to Buy Now
  Growth and income investors can buy these five top dividend stocks now, tomorrow, next week, or next year and hold for the long term.
  Dec 23, 2025
• Bet on These Top-Ranked Healthcare ETFs Before 2025 Ends
  XLV and similar healthcare ETFs are gaining momentum as strength in biotech, increased AI adoption, and rising defensive demand position the sector for year-end leadership.
  Dec 22, 2025
• What AbbVie (ABBV)'s Restructured OSE Immunology Partnership Means For Shareholders
  Earlier in December 2025, OSE Immunotherapeutics amended its partnership with AbbVie over the inflammatory disease candidate ABBV-230, with OSE taking back control of preclinical and Phase 1 work, at its own funding risk, while AbbVie kept exclusive rights to later-stage development and commercialization on unchanged economic terms. The revised ABBV-230 arrangement underlines AbbVie’s willingness to lean on partners’ early-stage immunology expertise while reserving control of potential...
  Dec 22, 2025
• Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
  Investors can expect steady dividend returns with these stocks.
  Dec 22, 2025
• 3 Dividend Growth Stocks Analysts Are Upgrading for 2026
  United Parcel Service, PepsiCo, and AbbVie are healthy dividend payers whose analyst trends support an outlook for price strength in 2026.
  Dec 21, 2025
• Pharma's $370B Bet on America: The ETF Plays for 2026
  Pharma ETFs like IHE are gaining traction as drugmakers pledge $370 billion to U.S. projects, fueling a new investment super-cycle heading into 2026.
  Dec 19, 2025
• Pfizer Down After It Issues Muted 2026 Outlook: How to Play the Stock
  Pfizer shares fall after a muted 2026 outlook, with projected modest revenue growth, lower COVID sales and deal dilution weighing on investor sentiment.
  Dec 19, 2025
• Top Midday Stories: Oracle, Others Form JV to Oversee TikTok in US; More Drugmakers to Announce US Drug Price Deals
  All three major US stock indexes were up in late-morning trading Friday, as the artificial-intellige
  Dec 19, 2025
• Nine Drugmakers Strike Deals With Trump, With More to Come
  The most recent pledges mean 14 of the 17 drugmakers targeted by Trump this summer have agreed to lower prices for the Medicaid program for low-income and disabled people, sell discounted drugs directly to consumers and launch new medicines for the same prices in the US as they do abroad. “American drug prices will come down fast and furious, and will soon be among the lowest in the developed world,” Trump said during an event in the Oval Office.
  Dec 19, 2025
• Vanguard Health Care Fund's Strategic Moves: Spotlight on AbbVie Inc
  Exploring the Fund's Recent Portfolio Adjustments
  Dec 19, 2025
• Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump
  Dow Jones stock Merck and eight other bellwether pharma companies struck drug-pricing agreements with the Trump administration on Friday.
  Dec 19, 2025
• 3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
  J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.
  Dec 18, 2025
• Is AbbVie a Millionaire Maker?
  AbbVie's third-quarter earnings were disappointing, but the company raised its full-year guidance and increased the dividend.
  Dec 18, 2025
• The 3 Income ETFs I’d Use to Offset Social Security
  If you are depending on Social Security for your retirement income, you might want to add reinforcements. While Social Security is tweaked annually in an attempt to keep up with the pace of inflation, its buying power has been dwindling in recent decades while the core inflation rate of 3% continues to hover above the ... The 3 Income ETFs I’d Use to Offset Social Security
  Dec 18, 2025
• Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors
  FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the appointment of Adrian Bot, M.D., Ph.D., to the Company’s Board of Directors. Dr. Bot is a biopharma executive with three decades of experience in research and development (R&D) with a focus on immune, cell, gene therapy and nanomedicines. He will serve as a member of the Science a
  Dec 18, 2025
• Has AbbVie’s 24.6% 2025 Rally Left Further Upside After Strong DCF Signals?
  Wondering if AbbVie is still a smart buy after its huge run, or if the value has already been squeezed out of the stock? Let us unpack what the current price really implies about its long term prospects. AbbVie has climbed 24.6% year to date and 32.0% over the last year, even after a softer last month with a 3.7% pullback from recent highs to around $223.67. That mix of strong multi year gains and short term wobble is exactly when valuation matters most. Recently, investors have been...
  Dec 17, 2025
• Analysts Split on AbbVie Inc. (ABBV) as BofA Cuts Target and HSBC Turns Bullish
  We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. TheFly reported on December 15 that Bank of America (BofA) lowered its price target for ABBV to $233 from $248 while maintaining a Neutral rating, reflecting a modestly reduced valuation outlook even as the company’s core business fundamentals remain solid. […]
  Dec 17, 2025
• Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
  Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
  Dec 17, 2025
• December 2025's Top Stocks Estimated Below Intrinsic Value
  As December 2025 unfolds, the U.S. stock market faces a challenging period with major indices like the S&P 500 and Dow Jones Industrial Average experiencing consecutive declines amid AI bubble concerns and rising unemployment rates. In such an environment, identifying undervalued stocks becomes crucial for investors seeking opportunities that may offer potential value relative to their intrinsic worth.
  Dec 17, 2025
• Want Decades of Passive Income? Buy This ETF and Hold It Forever.
  Can one ETF deliver decades of dividend income? This unique high-quality yield generator deserves a spot on your watchlist.
  Dec 17, 2025
• AbbVie price target lowered to $233 from $248 at BofA
  BofA lowered the firm’s price target on AbbVie (ABBV) to $233 from $248 and keeps a Neutral rating on the shares. The firm, which sees “a relatively clean setup” for growth at the high end of the peer group being balanced by a premium multiple and limited late-stage pipeline catalysts, is shifting its valuation basis to its FY27 estimates.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper
  Dec 16, 2025
• Cradle AI-powered protein engineering platform serving six of top 25 pharma leaders
  Cradle, an enterprise-grade AI software platform, today announced a series of milestones that signal a new phase of growth. The company saw rapid adoption across the pharma industry, with Cradle now running 50+ projects and powering drug discovery programs for six of the top 25 big pharma companies, including Johnson & Johnson, Abbvie, and Novo Nordisk. To continue expanding product capabilities and meet surging global demand, the company has doubled headcount across all departments and expanded
  Dec 16, 2025
• AbbVie (ABBV) Gains As Market Dips: What You Should Know
  The latest trading day saw AbbVie (ABBV) settling at $227.45, representing a +1.85% change from its previous close.
  Dec 15, 2025
• AbbVie Ranked #15 in the Inaugural Fortune 100 Best Companies to Work For Southeast Asia 2025 List
  AbbVie ASEAN has been ranked #15 in the inaugural Fortune Best Companies to Work For Southeast Asia 2025 list, in partnership with Great Place To Work®, highlighting workplaces across Singapore, Malaysia, Thailand and the Philippines.
  Dec 15, 2025
• AbbVie's Upside Potential Limited in Pipeline-Light 2026, BofA Securities Says
  AbbVie (ABBV) has a relatively clean growth profile with limited loss of exclusivity and growth like
  Dec 15, 2025
• The Best Dividend Stocks for Retirement Portfolios in 2026
  Retirement portfolios need growing income that outpaces inflation and safety that lets you sleep at night. The best retirement dividend stocks build reliable income streams that compound for decades. These companies raise dividends through recessions, market crashes, and business disruptions. We ranked them by dividend growth consistency, payout sustainability, and business resilience heading into 2026. ... The Best Dividend Stocks for Retirement Portfolios in 2026
  Dec 15, 2025
• AbbVie’s (ABBV) Options Flow Implies That the Smart Money Could Be Up to Something
  An intriguing quant signal combined with shifting sentiment in the derivatives market opens the possibility toward a bullish trade for ABBV stock.
  Dec 15, 2025
• Assessing AbbVie (ABBV) Valuation After HSBC Upgrade, Strong Earnings, and Dividend Hike
  AbbVie (ABBV) just caught a fresh tailwind after HSBC bumped the stock to a Buy, a move that comes on top of strong quarterly results, higher earnings guidance, and another dividend increase. See our latest analysis for AbbVie. Even with a softer 1 month share price return of 4.25 percent, AbbVie’s 24.45 percent year to date share price gain and 33.32 percent 1 year total shareholder return show momentum is still firmly building, helped by upbeat trial data, pipeline updates, and that fresh...
  Dec 13, 2025
• My Top 3 Healthcare Stocks to Buy in 2026
  These habitual market beaters can pull it off again.
  Dec 13, 2025
• 5 Dividend Powerhouses That Could Transform Your Portfolio Into a Wealth-Building Machine
  Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful current income with consistent dividend growth, backed by sustainable business fundamentals. These five stocks deliver that combination, each offering distinct advantages for compounding wealth over time. #5: Procter & Gamble (PG): The Steady Compounder Procter & Gamble earns ... 5 Dividend Powerhouses That Could Transform Your Portfolio Into a Wealth-Building Machine
  Dec 13, 2025
• 2 Mega-Cap Stocks with Exciting Potential and 1 We Ignore
  Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that most have already exploited their existing market opportunities and must invest heavily to expand further, a risky proposition.
  Dec 12, 2025
• AbbVie Slipped Below 50-Day SMA Last Week: How to Play the Stock
  AbbVie dips below its 50-day SMA, but strong immunology momentum and a resilient long-term trend keep the story compelling.
  Dec 12, 2025
• Here Are 2 Affordable Healthcare Stocks to Buy Heading Into 2026
  They could grow into their valuation over the next few years.
  Dec 12, 2025
• The Smartest Dividend Stocks to Buy With $5,000 Right Now
  See what solid dividends do for a portfolio after just five years.
  Dec 12, 2025
• Proven Income Generators: Ranking the Most Reliable Dividend Growth Stocks
  Dividend investing rewards patience. The best dividend stocks don’t just pay consistently—they raise payouts year after year, compounding income for shareholders who stay the course. Among thousands of publicly traded companies, only a select few have proven they can grow dividends through recessions, market crashes, and industry upheaval. We ranked these six proven dividend winners ... Proven Income Generators: Ranking the Most Reliable Dividend Growth Stocks
  Dec 12, 2025
• Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul
  AbbVie, McDonald’s, and Walmart offer growth, rising dividends, and valuation upside as investors seek blue-chip stability heading into 2026
  Dec 12, 2025
• HSBC Upgrades AbbVie (ABBV) to Buy, Raises Price Target to $265
  AbbVie Inc. (NYSE:ABBV) is included among the 15 Best Stocks to Buy for the Long Term. On December 10, HSBC increased its price target on AbbVie Inc. (NYSE:ABBV) from $225 to $265 and also upgraded the stock to Buy. Previously, on November 5, Piper Sandler reiterated a Buy rating on ABBV with a $289 price […]
  Dec 11, 2025
• $73 Billion Non-Opioid Therapeutics Industry Assessment, 2032 Featuring AbbVie, GlaxoSmithKline, Acorda Therapeutics, Allay Therapeutics, Alnylam Pharmaceuticals and Other Key Players
  The Non-Opioid Therapeutics Market is rapidly expanding due to increased demand for safer pain management Non-Opioid Therapeutics Market Non-Opioid Therapeutics Market Dublin, Dec. 11, 2025 (GLOBE NEWSWIRE) -- The "Non-Opioid Therapeutics Market - Global Forecast 2025-2032" has been added to ResearchAndMarkets.com's offering. This market research report focuses on the evolving landscape of the Non-Opioid Therapeutics Market. This sector has grown from USD 40.77 billion in 2024 to USD 43.78 billi
  Dec 11, 2025
• Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth
  ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.
  Dec 11, 2025
• Botox maker quietly launches plan to fend off rivals
  Botox has become so synonymous with anti-aging wrinkle treatments that many people use the name the same way they refer to tissues as Kleenex. But the brand power has a downside: Competitors have flooded the market, prices have dropped, and the company behind Botox is now making aggressive moves to ...
  Dec 11, 2025
• Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight
  The 67th American Society of Hematology (ASH) Annual Meeting, held December 6-9, 2025, in Orlando, Florida, showcased groundbreaking clinical advances in multiple myeloma treatment from leading biopharmaceutical companies. The conference featured unprecedented efficacy data demonstrating potential functional cures and innovative approaches across novel immunotherapies, bispecific antibodies, and next-generation targeted agents, signaling a major shift in how the disease is managed.
  Dec 11, 2025
• Is AbbVie Stock Too Cheap to Ignore at Today's Price?
  The drugmaker has plenty to offer investors.
  Dec 11, 2025
• 10 High-Yielding Dividend Stocks to Buy for 2026
  A stronger economy and Fed rate cuts could provide tailwinds for dividend stocks next year. Consider buying names such as AbbVie, FedEx, and Coca-Cola.
  Dec 11, 2025
• DLocal And 2 Other Stocks That May Be Priced Below Intrinsic Value
  As the United States market remains mixed ahead of a highly anticipated Federal Reserve decision on interest rates, investors are keenly observing how these shifts might impact stock valuations. In this environment, identifying stocks that may be priced below their intrinsic value can offer opportunities for those looking to capitalize on potential market inefficiencies.
  Dec 10, 2025
• HSBC highlights one pharma stock to buy and one to sell for 2026
  Investing.com -- HSBC shifted its ratings across U.S. large-cap pharmaceuticals in a note on Wednesday, led by Rajesh Kumar, upgrading AbbVie to Buy while cutting Biogen to Reduce, as the bank refreshed its 2026 sector outlook.
  Dec 10, 2025
• 3 Prominent Stocks Estimated To Be Trading At Up To 38.4% Below Intrinsic Value
  As U.S. investors keenly await the Federal Reserve's decision on interest rates, major indices like the S&P 500 have recently pulled back after nearing record highs, reflecting a cautious market sentiment. In such an environment, identifying stocks trading below their intrinsic value can present opportunities for those looking to capitalize on potential undervaluation amidst broader economic uncertainties.
  Dec 10, 2025
• Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls
  Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls
  Dec 10, 2025
• ASH 2025: AbbVie and Genmab’s Epkinly sets new standard in second-line FL
  AbbVie and Genmab’s Epkinly triplet is poised to become a new standard of care for FL.
  Dec 10, 2025
• This Dividend Pharma Giant Yielding 2.9% Just Got a Big Vote of Confidence
  Healthcare stocks have lagged the broader market for the past three years, weighed down by post-COVID earnings volatility, policy uncertainties around drug pricing, and a surge in tech-driven gains from the AI boom. The sector’s relative earnings growth averaged just 6% annually over that stretch, trailing the S&P 500‘s 15%, but signs of stabilization emerged ... This Dividend Pharma Giant Yielding 2.9% Just Got a Big Vote of Confidence
  Dec 10, 2025
• At A 8% Yield, Global X SuperDividend SDIV) Is One Of The Most Impressive High Income ETFs Today
  The Global X SuperDividend ETF (NYSEARCA:SDIV) generates its 8% yield by investing in 100 of the highest dividend-yielding equities across global markets. The fund holds stocks from developed and emerging markets spanning telecommunications, energy, materials, financials, and real estate. Income comes directly from dividends paid by underlying companies, making SDIV’s distributions entirely dependent on whether ... At A 8% Yield, Global X SuperDividend SDIV) Is One Of The Most Impressive High In
  Dec 10, 2025
• Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More
  Pre-Market Stock Futures: Futures are trading modestly lower as the big day has finally arrived: the Federal Reserve will wrap up its last meeting of 2025, and the odds still heavily favor a 25-basis-point rate hike. The worry hanging over traders is that many fear a “hawkish rate cut.” Where they do cut 25 basis ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More
  Dec 10, 2025
• Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal
  Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.
  Dec 9, 2025
• 3 Top Dividend Stocks to Buy in December
  Great dividends are only part of the attraction with these stocks.
  Dec 9, 2025
• 1 Major Factor Behind the Healthcare Sector's Recent Surge
  Blockbuster drugs are a major driver of the growth of healthcare stocks.
  Dec 9, 2025
• Medincell Publishes its Consolidated Half-Year Financial Results
  MONTPELLIER, France, December 09, 2025--Regulatory News: Christophe Douat, CEO of Medincell (Paris:MEDCL): "We are pleased with the company’s growth and momentum. We have entered the most transformative years in Medincell’s history. UZEDY delivers strong performance and the expected launch of olanzapine LAI next year is poised to be a major catalyst for Medincell’s growth. We keep advancing the third engine of our Shift to Growth strategy, with our first program in partnership with AbbVie leadin
  Dec 9, 2025
• Schwab’s SCHD ETF Is Mostly Solid, But 1 Top Holding Is Concerning
  The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) is a popular income choice for retirees. The fund generates income by holding a portfolio of dividend-paying U.S. stocks selected for their financial strength and dividend consistency. The ETF tracks the Dow Jones U.S. Dividend 100 Index, which screens for companies with at least 10 consecutive years of ... Schwab’s SCHD ETF Is Mostly Solid, But 1 Top Holding Is Concerning
  Dec 9, 2025
• AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know
  AbbVie (ABBV) concluded the recent trading session at $223.12, signifying a -1.31% move from its prior day's close.
  Dec 8, 2025
• Top-Ranked ETFs to Power Your Portfolio Higher
  With market tailwinds building and optimism returning, these top-ranked ETFs can help investors capture momentum safely.
  Dec 8, 2025
• How Investors May Respond To AbbVie (ABBV) Expanding Its Pipeline With New Migraine And Oncology Data
  In recent weeks, AbbVie has reported positive clinical and regulatory updates across several franchises, including strong Phase 3 migraine data for atogepant, encouraging early-stage blood cancer results for PVEK, and expanded Canadian reimbursement for SKYRIZI in ulcerative colitis. Together with an amended development arrangement for the early-stage antibody ABBV-230, these developments highlight how AbbVie is broadening its pipeline beyond its established immunology and neuroscience...
  Dec 8, 2025
• Why The Narrative Around AbbVie Is Shifting After New Immunology And Valuation Updates
  AbbVie’s latest narrative update leaves its fair value estimate steady at roughly $243.55 per share, even as small tweaks to the model reflect a slightly higher discount rate, a touch softer revenue growth outlook, and a modestly lower future valuation multiple applied to earnings. These shifts echo a market balancing act between enthusiasm over durable immunology growth, extended Rinvoq exclusivity, and sector rerating potential, and caution around pipeline execution risks, legacy asset...
  Dec 8, 2025
• OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development
  OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development Strategic Amendment Enhances OSE Immunotherapeutics’ Role in ABBV-230 Development While Preserving AbbVie’s Long-Term Commitment NANTES, France, December 8th, 2025 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced an amendment to its partnership agreement with AbbVie regarding ABBV-230, a monoclonal antibody designed to resolve chronic and severe inflammati
  Dec 8, 2025
• At ASH, Lilly makes case to widen Jaypirca use in leukemia, lymphoma
  In a head-to-head trial, Lilly’s drug was as effective as Imbruvica at inducing responses and displayed certain safety advantages that could make it a preferred treatment in early lines of care.
  Dec 7, 2025
• The Pharmaceutical Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.
  This drugmaker has a strong portfolio of best-selling drugs and a growing pipeline.
  Dec 6, 2025
• Pfizer (PFE) Up 3.9% Since Last Earnings Report: Can It Continue?
  Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 4, 2025
• Could Buying AbbVie Today Set You Up for Life?
  Don't bet against it.
  Dec 4, 2025
• How Strong Is AbbVie's Immunology Franchise After Humira's LOE?
  ABBV rebounds after Humira's LOE as soaring Skyrizi and Rinvoq sales drive a powerful immunology comeback.
  Dec 4, 2025
• How Stock Of The Day Genmab Is Leveraging An $8 Billion Deal To Stoke Its Next Chapter
  Genmab stock, Thursday's IBD Stock Of The Day, is just below an early entry in a cup case after announcing an $8 billion deal to buy Merus.
  Dec 4, 2025
• BeOne brought Brukinsa to the blood cancer mountaintop. Can it hit those heights again?
  The company’s chief medical officer discusses its trajectory with the blockbuster Brukinsa and its strong hematology pipeline.
  Dec 4, 2025
• Is It Too Late to Consider AbbVie After Its Strong Multi Year Share Price Rally?
  If you are wondering whether AbbVie is still attractive after its huge run, or if you are late to the party, you are in the right place to unpack what the current share price really implies. Even after a strong long-term climb, with the stock up 27.9% over the last year and 153.2% over five years, recent returns have cooled a bit, with a 3.2% dip in the last week but still a 2.9% gain over the past month and 25.0% year to date. Investors have been reacting to ongoing developments around...
  Dec 3, 2025
• AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
  AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
  Dec 3, 2025
• AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
  AbbVie (NYSE: ABBV) today announced it will unveil new data at the 2025 American Society of Hematology (ASH) Congress, showcasing continued advances in research across multiple blood cancers including — multiple myeloma (MM), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and amyloidosis (AL). Data across AbbVie's blood cancer portfolio will be featured in multiple oral and poster presentations including investiga
  Dec 2, 2025
• ReAlta Life Sciences Designates Dr. Howard Berman as Executive Chairman
  By Karen Roman ReAlta Life Sciences, Inc. announced the designation of Howard Berman, Ph.D., as Executive Chairman of its Board of Directors, effective immediately. “His proven track record in advancing innovative immunology-based therapies and creating value, positions ReAlta for disciplined growth and leadership in rare and inflammatory diseases,” said Kenji Cunnion, M.D., MPH, ReAlta’s co-founder, Chief […]
  Dec 2, 2025
• 2 Top Dividend Stocks to Buy Now and Hold For a Decade
  These healthcare leaders can make you money while you sleep.
  Dec 2, 2025
• If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now?
  AbbVie Inc. (NYSE:ABBV) engages in the research and development, manufacture, and sale of medicines and therapies worldwide. It is set to report its Q4 2025 earnings on Jan. 30. Wall Street analysts expect the company to post EPS of $3.36, up from ...
  Dec 1, 2025
• Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%
  Approval underscores Amneal’s advanced sterile manufacturing capabilities and expansion within complex ophthalmic therapies; Launch expected in Q1 2026 BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company’s cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials. The product is the generi
  Dec 1, 2025
• AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.73
  AbbVie Inc.'s ( NYSE:ABBV ) dividend will be increasing from last year's payment of the same period to $1.73 on 17th of...
  Nov 30, 2025
• Assessing AbbVie’s (ABBV) Valuation: Is There More Upside After Recent Performance?
  AbbVie (ABBV) shares are holding steady as investors assess the company’s ongoing performance following recent earnings. With key drugs still leading the portfolio, many are watching how AbbVie manages steady growth in a competitive sector. See our latest analysis for AbbVie. AbbVie’s share price has steadily climbed this year, with a year-to-date return of nearly 27%. The company’s recent updates have not slowed its momentum, as investor confidence continues to build. This is reflected in an...
  Nov 29, 2025
• 3 High-Yielding Dividend Growth Stocks That Can Generate Passive Income for Your Portfolio for Years
  These stocks have been raising their dividend payments annually for well over a decade, and they pay more than twice the S&P 500 average.
  Nov 29, 2025
• SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
  SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s disease (CD) and now for ulcerative colitis (UC), supported by evidence from pivotal phase 3 clinical trials including MOTIVATE, ADVANCE, FORTIFY (for CD), and INSPIRE, COMMAND (for UC).1,2AbbVie concludes letter of intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding SKYRIZI® f
  Nov 28, 2025
• IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick?
  Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.
  Nov 27, 2025
• AbbVie and Pfizer: A Closer Look at Two Pharma Heavyweights
  ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.
  Nov 26, 2025
• Is AbbVie Stock Outperforming the Nasdaq?
  AbbVie has outperformed the Nasdaq over the past year, and analysts are moderately optimistic about the stock’s prospects.
  Nov 26, 2025
• Centers for Medicare & Medicaid Services Unveils $12 Billion Net Savings From Reduction in Drug Prices
  The Centers for Medicare & Medicaid Services said Tuesday it expects to achieve net savings of 44%,
  Nov 26, 2025
• Enterprise Software, Health Care Stocks Miss Out on Broader Rally
  Most of the market was feasting on another helping of Thanksgiving week gains on Wednesday, but enterprise software and health care stocks were missing out on the celebration. Workday was the biggest laggard in the S&P 500 and among the fewer than 90 stocks in the index that were trading lower on Wednesday. Salesforce, another major player in enterprise software, reports quarterly results a week from today.
  Nov 26, 2025
• 1 Surging Stock with Exciting Potential and 2 Facing Challenges
  Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.
  Nov 25, 2025
• AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec
  National competition, in collaboration with adMare BioInnovations, demonstrates AbbVie's commitment to a thriving biotech ecosystem in Quebec One biotech will receive a year of laboratory and office space including access to shared equipment and services at no cost at the adMare Innovation Centre in Montreal, as well as access to AbbVie's scientific and business executives support and mentorshipApplications will be accepted until February 20, 2026. MONTREAL, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tod
  Nov 25, 2025
• AbbVie Insiders Sell US$41m Of Stock, Possibly Signalling Caution
  In the last year, many AbbVie Inc. ( NYSE:ABBV ) insiders sold a substantial stake in the company which may have...
  Nov 24, 2025
• Full FDA Approval of EPKINLY Combo Therapy Could Be a Game Changer for AbbVie (ABBV)
  AbbVie recently received full FDA approval for EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide for the treatment of adults with relapsed or refractory follicular lymphoma, following robust Phase 3 results showing significant improvement over standard of care. This landmark regulatory milestone addresses an unmet need in a challenging lymphoma type, potentially expanding AbbVie's reach in oncology and advancing treatment standards for patients with limited...
  Nov 24, 2025
• AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference
  AbbVie (NYSE: ABBV) will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025. Management will participate in a fireside chat at 7:30 a.m. Central time.
  Nov 24, 2025
• The Zacks Analyst Blog JPMorgan, Netflix, AbbVie and Ohio Valley Banc
  JPM shows solid operational strength as analysts highlight its NII outlook, fee pressures and expense trajectory through 2027.
  Nov 24, 2025
• How Recent Developments Are Shaping Analyst Views on AbbVie’s Future Edge
  Analysts have recently nudged AbbVie's consensus price target upward, rising slightly from $241.29 to $243.55 as updated sentiment filters through the market. This shift reflects increased optimism driven by strong performance in key growth areas and strategic business moves. Stay tuned to find out how investors can stay informed on evolving perspectives and future updates in AbbVie’s dynamic story. Analyst Price Targets don't always capture the full story. Head over to our Company Report to...
  Nov 24, 2025
• 5 Dividend Stocks to Hold for the Next 10 Years
  Investors should be able to count on steady dividends from these great stocks.
  Nov 24, 2025
• Investors bet on newer technology and indications for CGTs
  The industry is showing enthusiasm for novel technologies that improve safety and carry innovation potential including in vivo CAR-Ts.
  Nov 24, 2025
• Healthcare ETFs to Buy as Big Pharma Rapidly Integrates AI
  LLY's expanding AI alliances highlight how pharma-tech partnerships are transforming healthcare and lifting key sector ETFs like XLV.
  Nov 21, 2025
• Can Linzess Continue to Aid IRWD's Top Line After a Strong Q3?
  Ironwood gains momentum as rising U.S. demand for Linzess drives strong profit growth during the third quarter.
  Nov 21, 2025
• Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth
  ANI Pharmaceuticals' rare disease surge, led by Cortrophin Gel, drives major 2025 revenue gains despite softer ophthalmology sales.
  Nov 21, 2025
• Top Research Reports for JPMorgan Chase, Netflix & AbbVie
  JPMorgan's year-to-date gains, NII growth outlook and investment banking pipeline headline today's standout Zacks research picks.
  Nov 21, 2025
• AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know
  A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to
  Nov 21, 2025
• Fighting Cancer With 'Smart Bombs.' What New Treatments Mean For Wall Street.
  Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.
  Nov 21, 2025
• AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?
  ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.
  Nov 19, 2025
• 3 Cash-Producing Stocks We Think Twice About
  Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
  Nov 19, 2025
• AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
  AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
  Nov 19, 2025
• 3 Stocks Estimated To Be Trading Below Their Valuations In November 2025
  As the U.S. stock market experiences a period of volatility, with major indices like the S&P 500 and Dow Jones Industrial Average facing consecutive declines, investors are keenly observing the impact of high valuations in sectors such as technology. Amidst these fluctuations, identifying stocks that are potentially trading below their intrinsic value can offer opportunities for those looking to navigate current market conditions wisely.
  Nov 19, 2025
• Liver Failure Market Analysis Report 2025-2035: Gilead Sciences, AbbVie, and Boehringer Ingelheim Lead Advancements in Liver Failure Treatments and Artificial Liver Support Technologies
  Liver failure is a critical condition where the liver loses its ability to detoxify, synthesize proteins, and regulate biochemical processes. It can result from hepatitis, alcohol abuse, NAFLD, autoimmune diseases, or toxins. Key symptoms include jaundice, encephalopathy, ascites, and bleeding. The global liver failure market is expanding due to rising disease prevalence, enhanced healthcare access, and diversified therapies. Innovations in transplantation, artificial liver systems, and pharmaco
  Nov 19, 2025
• Metrorrhagia Market Analysis Report 2025-2035, Profiles of Pfizer, Sandoz, Bayer, Actavis Pharma, Noven Pharmaceuticals, Theramex, Pantarhei Bioscience, AbbVie, Neurocrine Biosciences, Merck
  The global metrorrhagia market is expanding due to an increasing prevalence of gynecological disorders like uterine fibroids and hormonal imbalances, fueling the demand for effective treatments. Despite challenges such as high diagnostic costs and limited awareness, advancements in hormonal and non-hormonal therapies are driving patient adoption. Key developments include targeted drug formulations, innovative surgical techniques, and emerging therapies like selective progesterone receptor modula
  Nov 19, 2025
• 2 Dividend Stocks to Hold Through Any Market Cycle
  Trying to build a portfolio that can survive recessions, inflation, and market volatility is one of the biggest challenges any investor can face. Unexpected market moves are hard to predict, and if you could make such predictions, not only would you be rich, but people would be throwing money at you, literally, to invest it ... 2 Dividend Stocks to Hold Through Any Market Cycle
  Nov 19, 2025
• Alkermes escalates bidding war; US biotech risks ‘falling behind’ China
  A bipartisan report warned Congress about China’s growing control over the pharmaceutical supply chain. Elsewhere, Alkermes sweetened its bid for Avadel and Moderna is investing $140 million in U.S. drug production.
  Nov 19, 2025
• Healthcare Rotation Underway: 3 Stocks Leading the Charge
  Are healthcare stocks finally back in fashion? After years of underperformance, a healthcare rotation is underway, led by these three innovative drug makers.
  Nov 19, 2025
• HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
  Hims & Hers Health may only generate a fraction of its competitors revenue, but its fiscal management and exponential growth point to a very bright future.
  Nov 19, 2025
• Is AbbVie’s 30% 2025 Surge Justified by Its Latest Drug Pipeline Wins?
  Wondering if AbbVie is a smart buy at today's price? You're not the only one. Let's dig into the numbers to find out how the market might be valuing the stock right now. AbbVie’s share price has jumped 7.0% in the past week and surged 30.4% year-to-date, putting its performance firmly in the spotlight and hinting at shifting investor sentiment. This momentum hasn’t come out of nowhere. Investors are reacting to positive developments from AbbVie’s drug pipeline and several high-profile FDA...
  Nov 18, 2025
• Sector Update: Health Care Stocks Rise Late Afternoon
  Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index up 0.3% and the Heal
  Nov 18, 2025
• AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
  AbbVie (NYSE: ABBV) today announced that EPKINLY® (epcoritamab-bysp), a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab and lenalidomide (EPKINLY + R2) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). This approval of EPKINLY is based on results from the pivotal Phase 3 EPCORE® FL-1 study that evaluated fixed duration EPKINLY + R2 compared to st
  Nov 18, 2025
• Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3
  ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.
  Nov 18, 2025
• Cervical Dystonia Research Analysis Report 2025-2035: Market Sees Intense Competition as Ipsen, Merz, and AbbVie Advance Therapies Through Strategic Expansions
  The global cervical dystonia market is thriving, driven by increased disease prevalence, advancements in neuromodulation techniques, and heightened awareness of movement disorders. Key factors include the widespread adoption of botulinum toxin therapies and deep brain stimulation for refractory cases, along with innovations in drug formulations. While barriers such as diagnosis delays and treatment cost persist, strategic efforts by industry leaders like Ipsen and AbbVie are shaping market dynam
  Nov 18, 2025
• LUPRON DEPOT® new strength receives Health Canada Approval for the Treatment of Advanced Prostate Cancer
  AbbVie (NYSE: ABBV) announced today that a new 6-month 45mg LUPRON DEPOT® (leuprolide acetate for extended-release injectable suspension) strength has received Health Canada approval for the treatment of advanced prostate cancer. LUPRON DEPOT is now available in four dosing options: 7.5 mg (1-Month), 22.5 mg (3-Month), 30 mg (4-Month), and 45 mg (6-Month).1 LUPRON DEPOT was initially approved by Health Canada for advanced prostate cancer in 1989, providing 36 years of proven clinical use in Cana
  Nov 17, 2025
• AbbVie Stock Falls 4% -- What Investors Need to Know
  It's no reason to stay up at night.
  Nov 17, 2025
• AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73
  AbbVie Inc. ( NYSE:ABBV ) has announced that it will be increasing its dividend from last year's comparable payment on...
  Nov 16, 2025
• Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
  These stocks pay income that investors can count on over the long run.
  Nov 15, 2025
• Pharma ETFs in Spotlight Following Robust Q3 Earnings Results
  Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.
  Nov 14, 2025
• AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer
  AbbVie (NYSE: ABBV) announced today the launch of Second Winds, a new short film that captures the powerful, deeply personal journeys of three people living with chronic lymphoma leukemia (CLL), a common type of blood cancer effecting hundreds of thousands of people in the United States.1,2 Each person's dynamic story reveals how facing a life-changing diagnosis can bring clarity and purpose, sparking a renewed commitment to staying active and embracing what truly matters in their lives.
  Nov 14, 2025
• AbbVie (ABBV): Evaluating Valuation Following Strong Results, Dividend Hike, and Key Strategic Shifts
  AbbVie (ABBV) is back in the spotlight after announcing strong quarterly results and a 6% dividend increase. The company also made waves by shifting strategy away from its Calico Life Sciences partnership and updating investors on several fronts. See our latest analysis for AbbVie. AbbVie shares have outpaced much of the market lately, supported by upbeat earnings, a hefty dividend increase, and high-profile strategic refocusing. With a 29% year-to-date share price return and a standout 46%...
  Nov 14, 2025
• Is that pharma influencer human or AI?
  Agentic AI is making its way into pharma marketing — and raising a slew of potential challenges around regulations and ethics.
  Nov 14, 2025
• IRWD Rises 110% in a Month: Should You Buy, Sell or Hold the Stock?
  Ironwood's 110% monthly surge follows upbeat third-quarter results and raised 2025 outlook, powered by increasing Linzess demand.
  Nov 13, 2025
• Stock Market News for Nov 13, 2025
  Wall Street closed mixed on Wednesday, pulled up by healthcare and financial stocks.
  Nov 13, 2025
• UCB’s Bimzelx and AbbVie’s Rinvoq Lead in EU5 Psoriatic Arthritis, Ankylosing Spondylitis, and Non-Radiographic Axial Spondyloarthritis Growth
  New insights from Spherix Global Insights reveal strong rheumatologist anticipation for next-generation oral and multi-pathway innovations, including Sotyktu, icotrokinra, and sonelokimab.Exton, PA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The 2025 Market Dynamix™: Psoriatic Arthritis and Ankylosing Spondylitis/Non-Radiographic Axial Spondyloarthritis (EU5) studies from Spherix Global Insights reveal a rapidly evolving treatment landscape, as rheumatologists expand use of next-generation IL-17 and JAK
  Nov 13, 2025
• Robert Bruce's Strategic Moves: AT&T Inc. Sees a -1.41% Portfolio Impact
  Insightful Analysis of Robert Bruce (Trades, Portfolio)'s Third Quarter 2025 13F Filing
  Nov 13, 2025
• Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month
  As National Alzheimer's Awareness Month spotlights new treatments, healthcare ETFs like XLV and VHT might gain fresh investor appeal.
  Nov 13, 2025
• Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls
  Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls
  Nov 13, 2025
• AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™
  AbbVie (NYSE: ABBV) today announced the 20 recipients of its second annual AbbVie Migraine Career Catalyst Award™ contest, an initiative that helps people living with migraine pursue their career and professional development goals. Each winner received $2,500 in financial support to invest in opportunities that advance their aspirations, from continued education and training to creating healthier, more supportive work environments.
  Nov 13, 2025
• 2 Strong Healthcare Stock Picks for Dividend Investors
  These top dividend payers could enrich a long-term investor's portfolio.
  Nov 13, 2025
• Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More
  Pre-Market Stock Futures: The stock futures are trading lower on Thursday, following another incredible day for the Dow Jones Industrials, while the rotation out of the NASDAQ and into technology is still gaining traction. The DJIA posted a record all-time high, closing at 48,254, up another 327 points or 0.68%. The S&P 500 just barely ... Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More
  Nov 13, 2025
• Sector Update: Health Care Stocks Rise Late Afternoon
  Health care stocks rose late Wednesday afternoon with the NYSE Health Care Index gaining 1.6% and th
  Nov 12, 2025
• Sector Update: Health Care Stocks Higher in Afternoon Trading
  Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index and the Health Care Sel
  Nov 12, 2025
• Three Companies Estimated To Be Priced Below Their Intrinsic Value In November 2025
  As the Dow Jones Industrial Average reaches new heights amid optimism surrounding a potential end to the U.S. government shutdown, investors are closely watching market fluctuations with mixed performances across major indices. In this environment, identifying stocks that may be undervalued becomes crucial, as these investments could offer opportunities for growth when priced below their intrinsic value.
  Nov 12, 2025
• BeOne, IBD Stock Of The Day, Breaks Out As It Takes On Cancer Giants J&J, AbbVie
  BeOne Medicines is Wednesday's IBD Stock Of The Day. The IBD 50 biotech is breaking out after a record-breaking quarter.
  Nov 12, 2025

ABBV Reviews

• DigitalDividend

  Dec 30, 2025

  $ABBV This company is like that wise old grandparent who always has the right remedy for what ails you—trustworthy and dependable!

  Buy

• EquityPulse

  Dec 29, 2025

  $ABBV With patent expirations lurking around the corner, it feels like an anxious waiting game, where profitability hangs by a thread!

  Sell

• ProfitVandal

  Dec 29, 2025

  $ABBV You might get more satisfaction from a placebo.

  Sell

• FiscalRogue

  Dec 29, 2025

  $ABBV Looks like they’ve run out of ideas and cash.

  Sell

• TheStockKnight

  Dec 28, 2025

  $ABBV Just another overhyped drugmaker riding the patent wave.

  Sell

• CapitalCrusher

  Dec 27, 2025

  $ABBV This one’s like a good pizza—always delivers satisfaction and keeps us coming back for more!

  Buy

• WallStreetWraith

  Dec 26, 2025

  $ABBV Pharmaceuticals are great, unless you're on the wrong side of them.

  Sell

• BullRaid

  Dec 26, 2025

  $ABBV When innovation stalls, expect the stock to stall too.

  Sell

• TheEquityEdge

  Dec 26, 2025

  $ABBV This established player in the pharmaceutical industry is continuously expanding its portfolio through strategic acquisitions and robust research initiatives. Their pipeline holds promise for future growth in diverse therapeutic areas.

  Buy

• PortfolioGremlin

  Dec 26, 2025

  $ABBV Big pharma got the moves, this one’s always schemin’!

  Buy

• BullishBard

  Dec 25, 2025

  $ABBV This company is like the wise grandparent of pharmaceuticals—always has the best advice and remedies!

  Buy

• Stonks4Days

  Dec 25, 2025

  $ABBV Big pharma vibes, stackin' those profits like a pro.

  Buy

• VolatilityNomad

  Dec 25, 2025

  $ABBV Pharmaceutical giant? More like a giant disappointment lately.

  Sell

• VolatilityCore

  Dec 24, 2025

  $ABBV A leader in the biopharmaceutical space, this company is known for its extensive research initiatives that target critical health challenges. Its innovative pipeline and commitment to improving patient outcomes reflect solid fundamentals.

  Buy

• TradeReckoner

  Dec 23, 2025

  $ABBV Looks good now, but watch out for that inevitable cliff.

  Sell

• BullRaid

  Dec 23, 2025

  $ABBV Cramming overpriced drugs down our throats like it’s a buffet.

  Sell

• EarningsEcho

  Dec 22, 2025

  $ABBV When your meds are the life of the party, you know you're doing something right. Let's just hope they bring snacks!

  Buy

• StockSpecter

  Dec 22, 2025

  $ABBV Hiding behind patents while innovation stagnates.

  Sell

• MarginMarauder

  Dec 21, 2025

  $ABBV This one’s like your favorite remedy – it just keeps coming up with solutions that make life a whole lot smoother!

  Buy

• OptionMatrix

  Dec 21, 2025

  $ABBV Renowned for its strong portfolio and commitment to research and development, this firm continues to advance in the pharmaceutical sector, showcasing resilience against market fluctuations.

  Buy

• RiskProtocol

  Dec 20, 2025

  $ABBV With a pipeline full of potential, it's a thrilling ride! But can this giant maintain its momentum in the face of looming competition?

  Buy

• TheEquityEdge

  Dec 19, 2025

  $ABBV Leveraging its strong pipeline of pharmaceutical products, this organization is well-placed for sustained growth in the healthcare sector. Investments in research and development highlight its dedication to innovation and improving patient outcomes.

  Buy

• HODLzilla

  Dec 19, 2025

  $ABBV Bringing the heat in the lab, these peeps got the cure!

  Buy

• Stonks4Days

  Dec 19, 2025

  $ABBV Pharma game strong, this player ain't going nowhere but up!

  Buy

• EarningsEcho

  Dec 19, 2025

  $ABBV This company has more meds than your grandma's cabinet. Seriously, they could probably cure the common cold if they wanted!

  Buy

• PaperHandsGone

  Dec 18, 2025

  $ABBV This heavyweight’s flexin’ hard; watch them dominate the scene!

  Buy

• MarginMarauder

  Dec 18, 2025

  $ABBV This stock is like that trusty old sweater – always there for you when it gets chilly, even if it’s been through the wash too many times.

  Sell

• MarketGlitch

  Dec 17, 2025

  $ABBV With multiple blockbuster drugs, the expectations are sky-high. Yet, the looming patent cliffs and competitive pressures are a source of constant anxiety. Will they sustain momentum or watch it all unravel?

  Buy

• ManiaBroker

  Dec 17, 2025

  $ABBV This stock is like that reliable friend who always shows up with pizza—totally dependable and brings the good stuff!

  Buy

• BullRunBoi

  Dec 17, 2025

  $ABBV Big dogs in the yard, makin' plays and droppin' knowledge.

  Buy

• HedgeMeNot

  Dec 16, 2025

  $ABBV Strong in the pharma game, steady vibes all around!

  Buy

• BearBreaker

  Dec 16, 2025

  $ABBV Has the charisma of a brick wall.

  Sell

• BearHunter

  Dec 15, 2025

  $ABBV This company is like your favorite aunt—always delivering on the good stuff when you least expect it. Thanks for the treats!

  Buy

• MarginMythic

  Dec 14, 2025

  $ABBV With patents expiring and competition on the rise, this powerhouse is at a crossroads. The tension is undeniable as it fights to maintain its legacy amid emerging threats.

  Sell

• TheQuantEdge

  Dec 13, 2025

  $ABBV In the pharma world, competition is fierce, and regulatory challenges are relentless! This titan faces constant pressure to innovate while managing costs. Can they keep the momentum?

  Sell

• FiscalEngine

  Dec 12, 2025

  $ABBV Renowned for its robust portfolio of pharmaceutical products, this company is well-positioned to address critical healthcare needs. Ongoing research and development efforts could pave the way for breakthroughs that enhance patient outcomes.

  Buy

• AlphaRogue

  Dec 12, 2025

  $ABBV When your meds are as dependable as your best buddy during finals week—you know, always there when you need them the most!

  Buy

• Stonks4Days

  Dec 12, 2025

  $ABBV Downward drift not slowing.

  Sell

• BearWithMe

  Dec 11, 2025

  $ABBV They’re dropping heat in the game, keep your eyes peeled!

  Buy

• TheLongPlay

  Dec 11, 2025

  $ABBV Long bias makes sense here.

  Buy

• TradeBlaze

  Dec 11, 2025

  $ABBV Smart money positioning long early.

  Buy

• OptionCipher

  Dec 11, 2025

  $ABBV Strong buying interest at critical levels.

  Buy

• OptionCipher

  Dec 11, 2025

  $ABBV Pharmaceuticals are a rollercoaster, and this giant is no exception. The fear of patent expirations looms large, creating a tense atmosphere!

  Sell

• CashWraith

  Dec 10, 2025

  $ABBV As the pharmaceutical landscape shifts, will this giant continue to lead, or are cracks beginning to show? It’s a tense balancing act that has investors watching closely for signs of weakness.

  Sell

• TheFiscalShade

  Dec 10, 2025

  $ABBV In the health game, playin' for keeps, strong moves comin'!

  Buy

• MarketRender

  Dec 10, 2025

  $ABBV This company is on the brink of something huge! The pressure is palpable, with every report causing my heart to race. Will they nail it or crumble under the weight?

  Buy

• TheAlphaDagger

  Dec 9, 2025

  $ABBV In the pharmaceutical race, this titan faces a storm of patent expirations and competition. Will their pipeline hold strong or falter under pressure?

  Sell

• ProfitVandal

  Dec 9, 2025

  $ABBV Downside volatility elevated.

  Sell

• YieldMyth

  Dec 9, 2025

  $ABBV Killing it in the health game, no competition in sight!

  Buy

• TheTradingVerse

  Dec 9, 2025

  $ABBV With a strong pipeline of innovative therapies, this pharmaceutical company is well-equipped to navigate the complexities of the healthcare market. Its commitment to research and development fuels optimism for long-term growth.

  Buy

• ProfitLancer

  Dec 8, 2025

  $ABBV Another overpriced drugmaker? Hope your portfolio can handle it.

  Sell

• BuyLowBro

  Dec 7, 2025

  $ABBV This one’s like the cool kid at school—smart, super popular, and always has the best parties (or, you know, drugs).

  Buy

• BullRaid

  Dec 7, 2025

  $ABBV Yet another pharma hoping for success without real innovation.

  Sell

• MarketWolf

  Dec 7, 2025

  $ABBV With a pipeline that could either lead to monumental success or disastrous failures, the tension is palpable. Will innovation pay off, or will the pressure lead to a breakdown?

  Buy

• DividendDegen

  Dec 6, 2025

  $ABBV Big shots makin' big plays, respect the hustle!

  Buy

• ChartSaber

  Dec 6, 2025

  $ABBV Large bids appearing out of nowhere.

  Buy

• MoonBagz

  Dec 6, 2025

  $ABBV Trend exhaustion visible at top.

  Sell

• AlphaHawk

  Dec 6, 2025

  $ABBV Yo, this player’s got mad game in the Pharma scene, for real!

  Buy

• YOLOTrader

  Dec 5, 2025

  $ABBV This healthcare giant is like the friendly neighbor who always has a first aid kit ready—only with more profit potential!

  Buy

• HODLzilla

  Dec 5, 2025

  $ABBV Big moves in the health game, they’re stacking that bread!

  Buy

• BearishBoi

  Dec 4, 2025

  $ABBV This company's meds are more popular than my dog on social media—now that's impressive!

  Buy

• CandleKnight

  Dec 4, 2025

  $ABBV Big pharma flexin’ on the health scene, always got your back.

  Buy

• RiskRanger

  Dec 4, 2025

  $ABBV Broken trendline signals trouble.

  Sell

• TheFiscalShade

  Dec 4, 2025

  $ABBV Strong short setup visible.

  Sell

• HODLzilla

  Dec 4, 2025

  $ABBV Very weak bullish attempts.

  Sell

• VolatilityStrike

  Dec 4, 2025

  $ABBV The company is recognized for its extensive product portfolio and robust pipeline, allowing it to maintain a solid market presence. Its focus on research and development positions it favorably for future growth.

  Buy

• EquityPulse

  Dec 3, 2025

  $ABBV New treatments could propel this pharmaceutical powerhouse to new heights, but will regulatory hurdles derail the excitement? The clock is ticking!

  Buy

• RiskVandal

  Dec 3, 2025

  $ABBV Just another overpriced pill-pusher hoping for a miracle.

  Sell

• AlphaRogue

  Dec 3, 2025

  $ABBV This company is a health superhero! Not sure if they’re saving the world or just giving out band-aids, but they’re doing something right!

  Buy

• WallStreetBandit

  Dec 2, 2025

  $ABBV This giant has its hands in too many cookie jars.

  Sell

• GainSurge

  Dec 2, 2025

  $ABBV This giant is making waves, but is it too big to fail or on the brink of a collapse? The suspense is unbearable, and every moment counts!

  Buy

• MarginMythic

  Nov 30, 2025

  $ABBV This giant has a lot riding on its next steps. Every shift in policy or market condition sends investors into a frenzy, seeking clarity in the chaos as the stakes continue to rise!

  Sell

• StonkRider

  Nov 30, 2025

  $ABBV This pharmaceutical giant is consistently pushing the envelope in drug development, with significant breakthroughs that demonstrate its ongoing commitment to addressing critical healthcare needs.

  Buy

• ProfitShade

  Nov 29, 2025

  $ABBV Killing it in the pharma game, they’re a force to be reckoned with!

  Buy

• CapitalCarnage

  Nov 29, 2025

  $ABBV A healthcare stock that just isn't healthy enough to thrive.

  Sell

• BullBrawler

  Nov 27, 2025

  $ABBV Riding on old drugs? Can't wait for the next scandal.

  Sell

• TradeBlitz

  Nov 27, 2025

  $ABBV The neighborhood’s go-to for health products—you'll feel like you've just discovered grandma's secret recipe for wellness!

  Buy

• CapitalNova

  Nov 27, 2025

  $ABBV As a leader in the pharmaceutical industry, this organization demonstrates a strong commitment to research and development, particularly in immunology and oncology. Its diverse portfolio positions it well for sustainable growth.

  Buy

• OptionShadow

  Nov 26, 2025

  $ABBV As a leader in biopharmaceuticals, this company continues to advance its pipeline with promising therapies. Its strong reputation and ongoing research initiatives position it well for future success.

  Buy

• CashClown

  Nov 26, 2025

  $ABBV Been around the block and still kickin’, can’t count this one out.

  Buy

• TheAlphaDagger

  Nov 25, 2025

  $ABBV In the pharmaceutical arena, every day is a high-wire act. Breakthroughs come with immense pressure, but the potential rewards could be life-changing. Will they navigate these treacherous waters successfully?

  Buy

• ProfitFang

  Nov 24, 2025

  $ABBV This company stands at the forefront of biopharmaceutical innovation, delivering groundbreaking treatments that address critical health needs, indicating strong potential for long-term growth.

  Buy

• AlgoAce

  Nov 24, 2025

  $ABBV They’re like the Swiss Army knife of medicine—got a solution for almost everything, except maybe your love life!

  Buy

• CandleCrusher

  Nov 22, 2025

  $ABBV With blockbuster drugs in the pipeline, things are heating up fast. But looming patent expirations could throw a wrench in the works at any moment!

  Buy

• TradeHex

  Nov 20, 2025

  $ABBV With a robust portfolio of pharmaceuticals and a focus on research-driven innovation, this company continues to lead in addressing complex health challenges. Its strategic acquisitions and pipeline developments enhance its competitive edge in the healthcare market.

  Buy

• WallStreetVandal

  Nov 20, 2025

  $ABBV Big pharma? Just another overhyped pill factory.

  Sell

• StonkDestroyer

  Nov 19, 2025

  $ABBV Once a giant, now just a shadow of its former self.

  Sell

• BullRunBoss

  Nov 19, 2025

  $ABBV They’re like that friend who always brings snacks to the party – everyone appreciates what they do!

  Buy

• TradeRebel

  Nov 18, 2025

  $ABBV In the ever-shifting pharmaceutical landscape, this giant feels the weight of expectations! Can they deliver breakthroughs that truly matter, or will they crumble under pressure?

  Sell

• YieldHunter

  Nov 18, 2025

  $ABBV With a diverse pharmaceutical portfolio, this company excels in delivering innovative treatments. Their ongoing investment in research and development suggests a strong pipeline of future products that could significantly impact healthcare outcomes.

  Buy

• YieldSlasher

  Nov 17, 2025

  $ABBV This company thinks it's a big deal, but it's just average.

  Sell

• TheChartCode

  Nov 17, 2025

  $ABBV Like a good meme, this company just keeps on giving. It’s the friend who always has your back!

  Buy

• MarketMemeLord

  Nov 17, 2025

  $ABBV Pharma heavyweight flexin', don’t sleep on this one.

  Buy

• ChartSaber

  Nov 17, 2025

  $ABBV Killing it in the pharma scene, they ain't slowing down anytime soon!

  Buy

• CandleBinary

  Nov 16, 2025

  $ABBV With a robust portfolio of innovative therapies, this company continues to lead the charge in transforming patient care. Its commitment to research and development positions it well for sustained growth in the dynamic healthcare sector.

  Buy

• CashWraith

  Nov 16, 2025

  $ABBV In the fierce battleground of pharmaceuticals, every breakthrough feels like a last-minute save in a nail-biting game. Can it maintain its momentum amidst fierce competition?

  Buy

• BearishBoi

  Nov 15, 2025

  $ABBV They’re working on treatments that could make you feel better than a surprise pizza delivery!

  Buy

• PriceBreaker

  Nov 15, 2025

  $ABBV This biopharmaceutical company continues to push the boundaries of innovation in healthcare. Their diverse portfolio and emphasis on research could provide significant advancements in treatment, appealing to investors seeking stability and growth.

  Buy

• ManiaBroker

  Nov 13, 2025

  $ABBV They’ve got more breakthroughs than a kid at a science fair! If you love life-saving meds, this one's got your back!

  Buy

• MarketMatrix

  Nov 12, 2025

  $ABBV This company is like a superhero in the healthcare world—saving lives and keeping your portfolio in good shape!

  Buy

• ChartPhantom

  Nov 12, 2025

  $ABBV This stock brings more power than your phone charger on 10%. Talk about a serious energy boost!

  Buy

• TradeBlaze

  Nov 12, 2025

  $ABBV With a diverse portfolio of healthcare solutions, this company demonstrates strong resilience in the pharmaceutical industry. Its ongoing commitment to innovation suggests a positive trajectory ahead.

  Buy

• TradeMatrix

  Nov 12, 2025

  $ABBV The pharmaceutical arena is cutthroat, and this company's recent developments have everyone on alert! Will their pipeline deliver breakthrough results, or are we looking at a potential setback? Tension is high!

  Buy

• CashKiller

  Nov 11, 2025

  $ABBV A healthcare giant or just a giant letdown? You decide.

  Sell

• AlphaRogue

  Nov 11, 2025

  $ABBV This company is like that overachiever in class — always coming up with new ways to tackle tough problems!

  Buy

• BearishBoi

  Nov 10, 2025

  $ABBV This stock brings the healing vibes like a warm blanket and hot cocoa on a snowy day. Cozy up!

  Buy

• AlphaDruid

  Nov 10, 2025

  $ABBV This stock seems like it's riding the waves of pharmaceutical innovation, but with the unpredictability of market reactions, it’s a constant battle of nerves. Will it emerge victorious or sink?

  Buy

• ShortRaid

  Nov 9, 2025

  $ABBV This pharmaceutical giant is known for its commitment to research and development, particularly in immunology and oncology. Their diverse portfolio and pipeline promise continued growth and the potential for future innovations.

  Buy

• DividendVandal

  Nov 9, 2025

  $ABBV This organization continues to lead in therapeutic innovation, particularly in immunology and oncology, reflecting its strong commitment to addressing unmet medical needs.

  Buy

• ShortSavior

  Nov 8, 2025

  $ABBV You’re betting on a fading star in a crowded field.

  Sell

• FOMOKing

  Nov 8, 2025

  $ABBV Solid play in the healthcare lane, ain't nothing to mess with!

  Buy

• TickerTakedown

  Nov 8, 2025

  $ABBV This stock is like your favorite superhero—always flying high and saving the day when things look grim!

  Buy

• CashWraith

  Nov 8, 2025

  $ABBV With a pipeline full of promise but surrounded by regulatory hurdles and patent cliffs, this player is under immense pressure. Can they innovate fast enough to keep the wolves at bay?

  Buy

• OptionShadow

  Nov 7, 2025

  $ABBV This company is at the forefront of biopharmaceutical innovation, delivering advanced therapies that significantly impact patient care. With a strong pipeline and consistent performance, it showcases resilience in a challenging market, appealing to those who prioritize health solutions with a meaningful societal contribution.

  Buy

• MarginBeast

  Nov 7, 2025

  $ABBV A big name, but even bigger problems lurking.

  Sell

• VolatileViking

  Nov 3, 2025

  $ABBV Chart's doing interpretive dance again, I swear. Rally so slow my WiFi.

  Sell

• TickerPhantom

  Nov 2, 2025

  $ABBV humming theta bull steady hurts it heavy eyes clean clean maybe levels queued today grind clean imo macro grind heating level-to-level vol sentiment crushing fast fast spike heavy spicy it

  Buy

• GainsJester

  Oct 29, 2025

  $ABBV run hurts maybe charts pumping queued buzzing mode diamond vol bull patience today tax humming loud grind fast tax imo sentiment

  Buy

• ChartPilot

  Oct 26, 2025

  $ABBV This volume deserves a standing ovation. Every breakout feels like a high-five from the trading.

  Sell

• FUDCrusher

  Oct 25, 2025

  $ABBV allergic soon to price meeting candles green action bagholders is

  Sell

• MoneyMage

  Oct 22, 2025

  $ABBV Perfect setup for disappointment right here. Technicals said no, emotions said yes.

  Buy

• HODLWarrior

  Oct 15, 2025

  $ABBV tape my doom fading feels candle liquidity whoa mode wild

  Sell

• StonkZombie

  Oct 14, 2025

  $ABBV Volatility got me questioning my life choices again. This is.

  Sell

• BullRaid

  Sep 29, 2025

  $ABBV to candles fake even allergic

  Sell

• StockStrider

  Sep 28, 2025

  $ABBV I laughed, I cried, I averaged down anyway. Perfect setup for.

  Sell

• BullishShade

  Sep 22, 2025

  $ABBV If charts could talk, this one would say, 'Let's ride!'.

  Buy

• LiquidLegend

  Sep 14, 2025

  $ABBV Even my coffee is less jittery than this price action.

  Buy

• PixelBroker

  Sep 10, 2025

  $ABBV it's it's spoken, ugly volume has whispering pain so and low

  Sell

• BuyLowBoi

  Sep 8, 2025

  $ABBV risk rough heating volume candle lower talking here cat on keeping tax keeping imo volume steady eyes nasty talking candle money soon steady

  Sell

• MarginBeast

  Sep 3, 2025

  $ABBV Even my stop loss feels safe right now. Even my.

  Sell

• RiskWraith

  Sep 1, 2025

  $ABBV level-to-level nasty wild talking mode beastly today mode heavy no patience keeping soon-ish on crushing trigger eyes heavy soon talking loud passed gains imo tax risk no it

  Buy

• StonkDestroyer

  Aug 19, 2025

  $ABBV This chart needs therapy. Market drama is better than Netflix.

  Sell

• AlphaDecoder

  Aug 11, 2025

  $ABBV energy smart theta soon-ish grind levels sentiment today today tape gains tbh macro soon-ish heat heavy whispers fast earnings now patience grind on noise here here diamond soon smart

  Buy

• CashCraze

  Jul 20, 2025

  $ABBV queued frankly macro tight sentiment dripping heating buzzing staying bid beastly bid whoa macro fire heavy noise

  Buy

• DividendVandal

  Jun 2, 2025

  $ABBV nimble level-to-level momentum patience watching gap feels trigger bid whoa clean charts printing

  Buy

• YieldMyth

  May 30, 2025

  $ABBV tax bounce sentiment grind king heat trend money go whispers pumping

  Buy

• BullishShade

  Apr 30, 2025

  $ABBV nimble trigger and bounce king spike fast tax tbh staying hurts energy bounce it patience king

  Buy

• TheTradingVerse

  Jan 27, 2025

  $ABBV printing feels smooth trigger passed tape here bounce clear money uptrend clean on heavy heavy it tbh

  Buy

• EquityPulse

  Dec 4, 2024

  $ABBV momentum king tight passed heater risk loud and breakout crushing clear

  Buy

• ShortCircuit

  Dec 4, 2024

  $ABBV gap diamond eyes flows energy ath run steady and noise tape on gap nasty risk charts humming vol

  Buy

• DiamondHandz

  Sep 25, 2024

  $ABBV run soon smart momentum here spike here eyes crushing breakout volume go strong

  Buy

• EquityPulse

  Sep 3, 2024

  $ABBV trigger crushing hard check risk strong noise flows go breakout soon charts

  Buy

• MarketMemeLord

  Jun 11, 2024

  $ABBV whoa here beastly no clean vol momentum earnings queued heating nimble bounce check soon on

  Buy

• MarketMyth

  Apr 8, 2024

  $ABBV tax risk dive eyes wall clear city whispers heavy tape hands ugly vol theta earnings wall no keeping loud

  Sell

• TickerTrickster

  Apr 1, 2024

  $ABBV tbh no macro hard run uptrend watching bid money volume talking grind gains crushing diamond tax patience sentiment

  Buy

• TradeFrenzy

  Dec 4, 2023

  $ABBV macro today my fading grind cliff on patience tbh buzzing earnings queued earnings mess tape soon trigger clear

  Sell